PDCD1 and neoplasm: The coexpression of LAG‐3 and PD‐1 on tumour‐infiltrating lymphocytes creates a synergistic immunosuppressive effect, which may persist even after PD‐1/PD‐L1‐targeted ICI monotherapy, leading to treatment resistance.106, 107, 108, 109